Besides, data from GDSC show preliminary evidence that mitomycin-C, doxorubicin and gemcitabine exhibit sensitivity for bladder cancer cells that harbor TP53 mutation, which provides evidence for the use of specific anti-tumor drugs to such patient in clinical practice (Fig. 3). Here, TP53 is linked to urinary bladder carcinoma.